The current clinical trial and drug regulatory process lags behind advances in research. The approval of the regulation is based on evidence of efficacy and safety collected during the main tests. Most experts agreed that the traditional approach to drug development is a blunt instrument, where a more focused experiment may be sufficient, rather than a one-time approach that is inefficient and wasteful.
According to a study by the New England Journal of Medicine, almost nine out of ten clinical trials do not meet FDA requirements and then do not reach the market. The project fails if they do not match the endpoints. The lack of efficiency and complex protocol are the main cause of failure. To reverse this trend, performance should be focused on the weak prognostic ability of the current experimental model.
Clinical research plays an important role in drug development and advancement in technologies such as drug positioning, therapeutic goal and prediction of drug efficacy, help researchers and pharmaceutical companies in drug development.
Traditional tests have a fixed parameter, which is determined in advance and remains constant in the process. One advancing approach to modernizing clinical trials and maximizing efficacy is adaptive trials that allow you to modify or replace certain parameters, such as sample size and treatment regimen, with intermediate results.
The main obstacle is that investment in clinical research is declining, as the government and stakeholders have tightened their budgets. As the main sponsors stabilize and the cost continues to grow, the clinical trial is financially squeezed. Pharmaceutical and medical manufacturing companies intend to cut budgets. These days, negotiations to end negotiations are the norm, not a single sponsor walks with a hole in money, and the majority responds to the mandate in order to save money, demanding that CROS provide unrealistic competitive budgets that are catastrophic. With a limited budget, myopia became the order of the day, and as a result both sponsors and the reputation of the CRO were affected.
A sharp reduction or unwillingness to adequately finance the project will lead to poor results. This simplified strategy is unrealistic and unstable. It is important to note that focusing solely on a short-term strategy will be disastrous in the long run. If a sustainable research climate is created, prosperity will inevitably grow.
Increasingly, the use of technology to optimize the protocol and improve the effectiveness of clinical research. The use of technology enables scientific experts to help them make decisions based on the data obtained. With the help of technology, organizations reduce costs and speed up the assessment process. The technology allows you to quickly and accurately determine the data and distribute information in real time. This can lead to better decision making on the protocol, patient recruitment and trial sites.
Here is a list of technologies affecting clinical trials today.
Risk Monitoring (RMB)
Companies use risk-based monitoring to identify and prioritize resources, identify risks related to the quality, safety of subjects, and the integrity of clinical trial data. Risk-based monitoring (RMB) may include targeted monitoring or triggered monitoring and reduced source document validation (SDV).
Traditionally, source data check (SDV) has been generated at 100% through on-site monitoring, a laborious approach. A reduced SDV limits the SDV score at the site, level of study, and level of subject.
The search for more important clinical trial management methods is characterized by risk-based monitoring, which attempts to manage resources without compromising clinical quality.
Variables of protocol compliance, data integrity, and patient safety, etc. Affect the deployment of assets.
The impact of technology on risk-based monitoring is significant, and there are currently clinical trial management systems (CTMS) and remote data collection (RDC), which can support a risk-based monitoring system. Some systems still support manual reporting and reporting of clinical trial data, so more reliable systems need to be installed to automatically notify and alert data, these alerts can be designed to notify those who should act when a problem occurs.
According to Medidata, the cost of on-site monitoring is close to 28.7% of the research and project management budget at 26.47%. When switching to yuan, monitors can spend their time more intelligently and reduce costs.
Electronic trial file
In the biopharmaceutical industry, each organization participating in clinical trials maintains a pilot master file containing several thousand pages of regulatory documents required for each clinical trial.
Using a paper-based or hybrid process-based basic file system to manage thousands of clinical documents, processes and tasks can be overwhelming and can cause mistakes or misunderstandings that can ruin a clinical trial and put it at risk for non-compliance.
Organizations typically used a corporate content management system (ECM) to manage the normative documents of clinical trials. ECM eTMF provides automated methods for indexing, archiving and reporting documents and content.
To exclude paper from a clinical trial study, electronic signing is used using digital signatures from trusted users. Globally, most countries, including the United States and many EU countries, accept digital signatures instead of wet signatures, thereby eliminating the need for verified documents.
The electronic trial master file (eTMF) offers a robust document management platform that allows research team members to get the quick insight they need to effectively manage clinical trials and accelerate time to market. Electronic document management processes are taken at a steady pace, as this becomes vital to business productivity, reduces the time it takes to develop biopharmaceutical products, and cuts costs.
eSource
In 2013, the FDA will release its Electronic Reference Data Guidance Document in clinical trials, since then sponsors and training sites have introduced and used eSource as a method for recording data in clinical trials.
The definition of an electronic source (eSource) is a clear concept - for collecting or processing raw data in electronic form, this data excludes raw data that was recorded on paper and copied to an electronic database. In eSource, the source data element itself must be electronic.
The advantage of eSource is appropriate, and the FDA approved it because it will be useful in: facilitating the input of electronic source data in real time during site visits, eliminates the need for data duplication, allows accurate and complete data using electronic prompts for inconsistent and missing data and reduces the likelihood of transcription errors.
Modernization and optimization of the data collection method is needed, with the result that most of the research work carried out by several pharmaceutical companies was mainly related to the creation of internal competence. As you move forward, it is imperative that standards and interoperability across different eSource sources come together to help create systems that provide accurate data in clinical studies.
Using the Clinical Data Repository (CDR) to optimize movements
The ability to effectively manage, report and analyze data is of paramount importance in clinical trials. The main obstacle is that clinical trial data are often entered by clinicians electronically or manually across multiple channels, including EDC, LIMS, CDMS and IVRS, and other systems, each of which has unique basic needs. This approach leads to the fact that the data ends in different databases, which makes it difficult and time-consuming to use and synchronize data.
There is confusion as to which institution or CDR is defined as opposed to a clinical data repository (CDW). CDRs can be viewed as consolidated storage and transmission of data for clinical trials, including security, workflow, and systems for performing everyday tasks under a single umbrella.
Centralizing the storage and management of data results is the goal of the CDR and provides a robust and reliable infrastructure that supports the analysis and management of clinical data, facilitating standardization and secure data transfer, allowing analytics and inter-seasonal analysis and leakage data from pipeline tests.
In conclusion, progress in clinical trials and development has become the backdrop to the success of science. While new technologies help streamline the protocol and save money, the future also requires sensible integration, linking the data collected during the tests with the data obtained during the clinical treatment phase, the research objectives should be aligned with the protocol to eliminate actions that do not support end points.
